NasdaqGS:SPRO

Stock Analysis Report

Executive Summary

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States.

Rewards

Loading interface...

Risk Analysis

Loading interface...

Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Spero Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Information is not available.


Market Performance


7 Day Return

-1.8%

SPRO

-0.3%

US Biotechs

0.3%

US Market


1 Year Return

77.7%

SPRO

14.6%

US Biotechs

18.5%

US Market

Information is not available.

Information is not available.


Shareholder returns

SPROIndustryMarket
7 Day-1.8%-0.3%0.3%
30 Day13.4%7.3%1.5%
90 Day1.6%15.4%5.7%
1 Year77.7%77.7%15.6%14.6%21.1%18.5%
3 Yearn/a28.7%24.7%45.9%36.4%
5 Yearn/a7.5%2.6%71.4%52.5%

Price Volatility Vs. Market

How volatile is Spero Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Spero Therapeutics undervalued compared to its fair value and its price relative to the market?

2.4x

Price to Book (PB) ratio


Share Price vs. Fair Value

Information is not available.

Information is not available.


Price To Earnings Ratio

Information is not available.

Information is not available.


Price to Earnings Growth Ratio

Information is not available.


Price to Book Ratio

Information is not available.


Next Steps

Future Growth

How is Spero Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

11.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Information is not available.

Information is not available.

Information is not available.

Information is not available.

Information is not available.


Earnings per Share Growth Forecasts


Future Return on Equity

Information is not available.


Next Steps

Past Performance

How has Spero Therapeutics performed over the past 5 years?

-17.4%

Historical annual earnings growth


Earnings and Revenue History

Information is not available.

Information is not available.


Past Earnings Growth Analysis

Information is not available.

Information is not available.

Information is not available.


Return on Equity

Information is not available.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Spero Therapeutics's financial position?


Financial Position Analysis

Information is not available.

Information is not available.


Debt to Equity History and Analysis

Information is not available.

Information is not available.

Information is not available.

Information is not available.


Balance Sheet

Information is not available.

Information is not available.


Next Steps

Dividend

What is Spero Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Years0%

Current dividend yield vs market & industry

Information is not available.

Information is not available.


Stability and Growth of Payments

Information is not available.

Information is not available.


Current Payout to Shareholders

Information is not available.


Future Payout to Shareholders

Information is not available.


Next Steps

Management

What is the CEO of Spero Therapeutics's salary, the management and board of directors tenure and is there insider trading?

1.9yrs

Average management tenure


CEO

Ankit Mahadevia (38yo)

4.8yrs

Tenure

US$721,324

Compensation

Mr. Ankit Mahadevia, MD, MBA serves as the Chief Executive Officer and President of Spero Therapeutics, LLC. Mr. Mahadevia Co-founded of Spero Therapeutics, Inc. in 2013 and has been its Chief Executive Of ...


CEO Compensation Analysis

Information is not available.

Information is not available.


Management Age and Tenure

1.9yrs

Average Tenure

60yo

Average Age

Information is not available.


Board Age and Tenure

5.6yrs

Average Tenure

62yo

Average Age

Information is not available.


Insider Trading

Information is not available.


Ownership Breakdown

Information is not available.


Management Team

  • Tom Parr (65yo)

    Chief Scientific Officer

    • Tenure: 5.7yrs
    • Compensation: US$450.89k
  • Ian Critchley

    Head of Clinical Microbiology

    • Tenure: 1.7yrs
  • Ankit Mahadevia (38yo)

    Co-Founder

    • Tenure: 4.8yrs
    • Compensation: US$721.32k
  • Sharon Klahre

    Senior Director of Investor Relations

    • Tenure: 0yrs
  • Jay Blackington

    Head of People Strategy & Culture

    • Tenure: 1.1yrs
  • Melissa Stundick

    Executive Director of Strategic Alliances

    • Tenure: 0yrs
  • Cristina Larkin (49yo)

    Chief Operating Officer

    • Tenure: 2.3yrs
    • Compensation: US$533.80k
  • David Melnick (67yo)

    Chief Medical Officer

    • Tenure: 1.9yrs
    • Compensation: US$1.63m
  • Steve DiPalma (60yo)

    Interim CFO & Treasurer

    • Tenure: 0.08yrs
  • Susannah Walpole

    Head of Clinical Operations

    • Tenure: 1.9yrs

Board Members

  • Jean-François Formela (62yo)

    Independent Director

    • Tenure: 6.8yrs
    • Compensation: US$92.15k
  • Frank Thomas (49yo)

    Independent Director

    • Tenure: 2.4yrs
    • Compensation: US$102.15k
  • Milind Deshpande (62yo)

    Chairman

    • Tenure: 0yrs
    • Compensation: US$122.03k
  • Eric Gordon

    Scientific Advisors

    • Tenure: 5.6yrs
  • George Drusano

    Clinical Advisor

    • Tenure: 5.6yrs
  • Steve Gilman (66yo)

    Scientific Advisor

    • Tenure: 0yrs
  • Patrick Vink (56yo)

    Independent Director

    • Tenure: 4.3yrs
    • Compensation: US$100.65k
  • Gordon Archer (75yo)

    Clinical Advisor

    • Tenure: 5.6yrs
  • Ankit Mahadevia (38yo)

    Co-Founder

    • Tenure: 4.8yrs
    • Compensation: US$721.32k
  • Paul Ambrose

    Clinical Advisor

    • Tenure: 5.6yrs

Company Information

Spero Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Spero Therapeutics, Inc.
  • Ticker: SPRO
  • Exchange: NasdaqGS
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$214.809m
  • Shares outstanding: 19.13m
  • Website: https://sperotherapeutics.com

Number of Employees


Location

  • Spero Therapeutics, Inc.
  • 675 Massachusetts Avenue
  • 14th Floor
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SPRONasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 2017
2HADB (Deutsche Boerse AG)YesCommon StockDEEURNov 2017

Biography

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the Uni ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/09 00:58
End of Day Share Price2019/12/06 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.